HARS2

Across TCGA pan-cancer cohorts, HARS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HARS2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HARS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HARS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where HARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.422	0.972	.003	29	view →
LSCC	OS	Median	III,IV	0.494	0.923	.005	20	view →
PDAC	OS	Quartile	II,III,IV	0.769	0.931	.011	10	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.929	.020	3	view →
LUAD	DFS	Quartile	All	0.887	0.996	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HARS2–CCRCC (OS)

Open the CCRCC breakdown →